URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Information about Toremifene
Liver safety of Toremifene
Long term toremifene therapy has been associated with development of fatty liver, steatohepatitis, cirrhosis, and rare instances of clinically apparent acute liver injury.
Mechanism of action of Toremifene
Toremifene (tor em' i feen) is a selective estrogen receptor modulator, similar to tamoxifen, that has tissue specific actions with antiestrogenic activity on breast tissue, but estrogenic activity (agonism) on bone and the cardiovascular system.
FDA approval information for Toremifene
Toremifene was approved for use in the United States in 1997 and its indications are limited to the treatment of estrogen-receptor positive (or unknown) metastatic breast cancer in postmenopausal women. Unlike tamoxifen, toremifene has not been approved as a means of prevention of de novo breast cancer in high risk patients or for prevention of recurrence of breast cancer.
Dosage and administration for Toremifene
Toremifene is available in tablets of 60 mg under the brand name Fareston. The recommended dose is 60 mg by mouth once daily.
Side effects of Toremifene
Common side effects include hot flashes, sweating, nausea, dizziness, peripheral edema and vaginal discharge. Rare, but potentially severe adverse events include tumor flare (transient worsening soon after starting therapy), prolongation of the QTc interval, venous thrombosis and pulmonary embolism and endometrial (uterine) carcinoma.